Zacks Investment Research provided stock analysis and ratings for Insulet (Q104480795), which is part of the Omnipod Insulin Management System (PDM), on August 27, 2025.
2 reports, 1 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zacks Investment Research provided stock analysis and ratings for Insulet (Q104480795), which is part of the Omnipod Insulin Management System (PDM), on August 27, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Insulet (United States)
insulin delivery device company
Nothing else this week.
-
PDM
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksHere's Why Insulet (PODD) is a Strong Growth Stock Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an inve
- ZacksWhy Insulet (PODD) is a Top Momentum Stock for the Long-Term It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all